CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

The European drug authority recommends refusal of marketing authorization due to evidence gaps in quality and efficacy.

Pregabalin was associated with an increased risk for heart failure relative to another widely used gabapentinoid, based on an ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has ...

Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.

Certara Simcyp Simulator becomes first software platform to receive EMA qualification opinion for PBPK modelling: Radnor, Pennsylvania Tuesday, August 5, 2025, 12:00 Hrs [IST] Cer ...

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...

Discontinuation rates in pediatric trials remain high, reflecting logistical and clinical obstacles. To overcome these hurdles, clinical research organizations can assist - re-thinking pediatric trial ...

Oncology company BeOne Medicines' investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, has received priority medicines (PRIME) designation from the European Medicines Agency (EMA) to ...